Organization | The Christie NHS Foundation Trust

The Christie NHS Foundation Trust Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3

Founded: Manchester United Kingdom (1887)

Organization Overview

First Clinical Trial

1992

NCT00003859

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Anna Thomason | Brynn Chappell | Christie Hospital, Manchester | Christie Hospital, Manchester, UK | Christie Hospital NHS | Christie Hospital NHS Foundation Trust | Christie Hospital, UK | Christie NHS Foundation Trust | Department of Medical Oncology, Christie Hospital, Manchester, UK | Dpt. Clinical Oncology, The Christie, Manchester. | Fiona Thistlethwaite | Heather Driscoll | Prof Corinne Faivre-Finn | Professor Robert Hawkins | Sally Falk | The Christie Hospital | The Christie Hospital, Manchester | The Christie Hospital, Manchester, UK | The Christie Hospital, UK | The Christie National Health Service (NHS) Foundation Trust | The Christie NHS Foundation Trust | The Christie NHS Foundation Trust and the University of Manchester | The Christie NHS Foundation Trust - Christie Hospital | The Christie NHS Foundation Trust Clinical Trials Unit; UK | The Christie NHS Foundation Trust Manchester, UK | The Christie NHS Foundation Trust, Manchester, UK | The Christie NHS Foundation Trust, Manchester, United Kingdom | The Christie NHS Foundation Trust, The University of Manchester | The Christie NHS Foundation Trust, UK | The Christie research (Manchester)

Active Ingredients

Drugs in Phase 3 Trials (43)

alectinib (alecensa) (2 trials)

allogeneic hematopoietic stem cells (Hemacord) (1 trial)

amsacrine (1 trial)

asparaginase (elspar) (3 trials)

atezolizumab (Tecentriq) (3 trials)

carboplatin (paraplatin) (5 trials)

cediranib (4 trials)

cisplatin (platinol) (8 trials)

cobimetinib (cotellic) (2 trials)

cyclophosphamide (cytoxan) (10 trials)

cytarabine (cytosar-u) (2 trials)

daunorubicin (cerubidine) (2 trials)

doxorubicin (Doxil) (4 trials)

entrectinib (Rozlytrek) (2 trials)

epirubicin (ellence) (1 trial)

etoposide (vepesid) (4 trials)

fluorouracil (efudex) (3 trials)

fulvestrant (faslodex) (4 trials)

gastrin 17 vaccine (Gastrimmune) (1 trial)

gemcitabine (gemzar) (6 trials)

idarubicin (idamycin) (1 trial)

ifosfamide (ifex) (2 trials)

lanreotide (somatuline depot) (1 trial)

leucovorin (2 trials)

levoleucovorin (fusilev) (1 trial)

mercaptopurine (purinethol) (1 trial)

mitomycin (mutamycin) (1 trial)

mitoxantrone (novantrone) (2 trials)

naltrexone (revia) (3 trials)

Nimorazole (nulogyl) (1 trial)

nivolumab (opdivo) (1 trial)

oxaliplatin (eloxatin) (2 trials)

paclitaxel (taxol) (4 trials)

pegaspargase (oncaspar) (1 trial)

pertuzumab (perjeta) (2 trials)

prednisone (meticorten) (2 trials)

telotristat ethyl (xermelo) (1 trial)

tioguanine (Lanvis) (1 trial)

trastuzumab (herceptin) (2 trials)

urea (3 trials)

vemurafenib (zelboraf) (2 trials)

vinblastine (velban) (1 trial)

vincristine (oncovin) (5 trials)

Drugs in Phase 2 Trials (46)

abemaciclib (verzenio) (1 trial)

acetylsalicylic acid (aspirin) (2 trials)

aldesleukin (Proleukin) (6 trials)

anastrozole (arimidex) (2 trials)

avelumab (bavencio) (2 trials)

azd-4547 (1 trial)

barasertib (2 trials)

bemcentinib (1 trial)

bevacizumab (avastin) (3 trials)

bexarotene (targretin) (1 trial)

bryostatin (1 trial)

cetuximab (erbitux) (2 trials)

cotil-01 (1 trial)

docetaxel (taxotere) (3 trials)

exatecan (1 trial)

fludarabine (fludara) (5 trials)

fosbretabulin (1 trial)

histamine (1 trial)

ibritumomab tiuxetan (Zevalin) (2 trials)

irinotecan (Camptosar) (3 trials)

lansoprazole (prevacid) (2 trials)

lenalidomide (revlimid) (1 trial)

letrozole (femara) (2 trials)

modified vaccinia ankara-5t4 vaccine (1 trial)

mogamulizumab (poteligeo) (1 trial)

ny-eso-1 t cells (1 trial)

olaparib (lynparza) (6 trials)

pasireotide (signifor) (1 trial)

pazopanib (votrient) (1 trial)

pembrolizumab (keytruda) (2 trials)

pexidartinib (Turallo) (1 trial)

rituximab (rituxan) (2 trials)

rucaparib (rubraca) (1 trial)

Samuraciclib (1 trial)

scib1 (1 trial)

selumetinib (Koselugo) (4 trials)

sulforaphane (1 trial)

tamoxifen (nolvadex) (2 trials)

tegafur (1 trial)

temozolomide (temodar) (1 trial)

tetrahydrocannabinol (2 trials)

tumour infiltrating lymphocytes (1 trial)

uracil (1 trial)

util-01 (1 trial)

varlilumab (1 trial)

voriconazole (vfend) (1 trial)

Drugs in Phase 1 Trials (14)

azd0156 (1 trial)

azd-3514 (1 trial)

azd6738 (1 trial)

cd19 car-t cells (1 trial)

cyad-101 (1 trial)

entinostat (1 trial)

Fosgemcitabine (acelarin) (1 trial)

mfe23 scfv-expressing autologous anti-cea mfez t lymphocytes (1 trial)

niraparib (zejula) (1 trial)

pemetrexed (alimta) (2 trials)

trastuzumab emtansine (kadcyla) (1 trial)

vinorelbine (navelbine) (1 trial)

vistusertib (1 trial)

Drugs in Other Trials (5)

goserelin (zoladex) (1 trial)

pegvisomant (somavert) (1 trial)

povidone (1 trial)

raloxifene (evista) (1 trial)

zibotentan (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Aspergillosis (Phase 2)

Biliary Tract Neoplasms (Phase 3)

Breast Neoplasms (Phase 3)

Carcinoid Heart Disease (Phase 3)

Carcinoid Tumor (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Merkel Cell (Phase 1)

Carcinoma, Neuroendocrine (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 3)

Carcinosarcoma (Phase 2)

Central Nervous System Neoplasms (Phase 3)

Cholangiocarcinoma (Phase 3)

Colorectal Neoplasms (Phase 2)

Endometrial Neoplasms (Phase 2)

Ependymoma (Phase 2)

Esophageal Neoplasms (Phase 1)

Gallbladder Neoplasms (Phase 3)

Glioblastoma (Phase 2)

Head and Neck Neoplasms (Phase 3)

Heart Diseases (Phase 3)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Non-Hodgkin (Phase 1)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Malignant Carcinoid Syndrome (Phase 3)

Melanoma (Phase 2)

Mesothelioma (Phase 2)

Mixed Tumor, Mullerian (Phase 2)

Myelodysplastic Syndromes (Phase 3)

Nelson Syndrome (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Unknown Primary (Phase 3)

Nervous System Neoplasms (Phase 3)

Neuroectodermal Tumors (Phase 3)

Neuroectodermal Tumors, Primitive (Phase 3)

Neuroendocrine Tumors (Phase 3)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Preleukemia (Phase 3)

Prostatic Neoplasms (Phase 1)

Rectal Neoplasms (Phase 1)

Recurrence (Phase 1)

Sarcoma (Phase 3)

Sarcoma, Kaposi (Phase 2)

Serotonin Syndrome (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 3)

Stomach Neoplasms (Phase 1)

Syndrome (Phase 3)

Triple Negative Breast Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 84
# of Trial APIs: 108